Payer objection handling matrix for CDK4/6 inhibitor: country-specific HTA responses across CEE markets
Payers raised different objections in every market
A global pharma company was preparing HTA submissions for a CDK4/6 inhibitor across 5 CEE markets. Each national payer body had distinct objections — from comparator choice and subgroup data availability to budget impact assumptions and indirect treatment comparison methodology.
The Medical and Access teams had a single global value dossier, but no structured framework to anticipate and address country-specific payer pushback. Local affiliates were preparing responses independently, leading to inconsistent messaging and duplicated effort.
With submissions staggered across the year, each affiliate was effectively reinventing the process — spending significant preparation time on objections that other markets had already encountered and resolved.
The client needed a systematic, evidence-backed objection matrix that would equip local teams with pre-validated responses — aligned with global messaging but tailored to local HTA expectations.
What we did
Measurable impact
The objection-response matrix became the primary HTA preparation tool across all 5 CEE markets. Local teams reported significantly reduced preparation time for payer meetings. The structured approach supported positive reimbursement decisions in 4 of the 5 target markets within the first 12 months. The master matrix was subsequently adapted by the global Market Access team as a template for future product launches in the region.
Tell us what you’re working on — we’ll show you relevant cases and suggest the fastest path forward.
From the field:
evidence & practice
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.